Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Year: 2014
Type: article
Source: Molecular Cancer Therapeutics
Institution: Bayer (Germany)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
Funder: Bayer HealthCare
OpenAlex ID: W2138654358
